SCHEMBL6418752

SCHEMBL6418752

COc1ccc2c(c1)C(=O)N(C)C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C2C(=O)NCc1ccncc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.55
KMT2A Q03164 3/20 0.51
CYP3A4 P08684 2/20 0.51
MEN1 O00255 2/20 0.51
CYP2C9 P11712 1/20 0.51
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.43
KCNH2 Q12809 1/20 0.41
SCN5A Q14524 1/20 0.41
SCN9A Q15858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
FLT1 P17948 2/20 0.40
KDR P35968 2/20 0.40
NPC1 O15118 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6410227 0.87 HSD17B10 (0.56) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6410802 0.84 GAA (0.47) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6411886 0.84 KMT2A (0.55) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6416797 0.80 GAA (0.44) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6418322 0.80 HSD17B10 (0.55) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6417863 0.79 HSD17B10 (0.49) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6413067 0.78 HSD17B10 (0.70) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6416285 0.76 HSD17B10 (0.50) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6411266 0.75 L3MBTL1 (0.58) NPSR1KMT2ACYP3A4MEN1CYP2C9
SCHEMBL6418414 0.75 ALDH1A1 (0.47) NPSR1KMT2ACYP3A4MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD NPSR1 4805/4885KMT2A 3478/4885CYP3A4 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.